Imagion Biosystems has released its Annual Report for the year ended 31 December 2021. See linked documents below.
2021 Clinical Highlights:
- Multiple patients enrolled and completed the MagSense® HER2 Breast Cancer Phase I Study
- Four clinical sites in VIC, NSW, and QLD are participating in the Phase I Study
2021 Operational Highlights:
- Secured new premises expanding R&D and manufacturing capabilities
- CSIRO funds support prostate cancer preclinical research at Monash University’s Biomedicine Discovery Institute
- Collaboration with Patrys Limited looks towards a potential new imaging agent for brain cancer
- Joint Development Agreement with Global Cancer Technology aims to develop nanoparticle technology for treating breast cancer
- Revenue from sales of IBX’s super-paramagnetic iron oxide nanoparticles to external parties remains steady
2021 Corporate Highlights:
- Imagion received $2.6 million in R&D tax incentives
- Cash balance of $13.4 million as of 31 December 2021
- Exercise of listed options delivering over $5.5 million to the Company
- Dr. Yalia Jayalakshmi joins IBX as Chief Development Officer
Executive Chairman and CEO Bob Proulx concludes in the Annual Report, “Imagion starts 2022 in a strong financial position with our clinical study well underway and momentum in our research programs. We are looking forward to bringing our Phase I study to conclusion and executing our next phase of development. We are grateful to all our stakeholders – collaborators, patients that participate in the study, employees, and shareholders – for their ongoing support and we look forward to updating you with progress throughout the year.”
